Whole-exome sequencing for the identification of rare variants in primary immunodeficiency genes in children with sepsis - a prospective population-based cohort study. by Borghesi, Alessandro et al.
 © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases 
Society of America. 
This is an Open Access article distributed under the terms of the Creative Commons 
Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-
nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any 
medium, provided the original work is not altered or transformed in any way, and that the 
work is properly cited. For commercial re-use, please contact 
journals.permissions@oup.com 
Whole-exome sequencing for the identification of rare variants in primary immunodeficiency 
genes in children with sepsis - a prospective population-based cohort study 
Alessandro Borghesi, MD, PhD
1,2,3*
, Johannes Trück, MD, DPhil
4,5*
, Samira Asgari, PhD
1,2,6,7
, 
Vanessa Sancho-Shimizu, PhD
8,9
, Philipp KA Agyeman, MD
10
, Evangelos Bellos, PhD
8
, Eric 
Giannoni, MD
11
,
 
Martin Stocker, MD
12
, Klara M Posfay-Barbe, MD
13
, Ulrich Heininger, MD
14
, Sara 
Bernhard-Stirnemann, MD
15
, Anita Niederer-Loher, MD
16
, Christian R Kahlert, MD
17
, Giancardlo 
Natalucci, MD
17
, Christa Relly, MD
4
, Thomas Riedel, MD
18
, Claudia E Kuehni, MD, PhD
19
, Christian 
W. Thorball
1,2
, Nimisha Chaturvedi
1,2
, Federico Martinon-Torres, MD
20,21
, Taco W Kuijpers, MD, 
PhD
22
, Lachlan Coin, PhD
23
, Victoria Wright, PhD
8
, Jethro Herberg, MRCPCH, PhD
8
,
 
Michael Levin, 
MD, PhD
8
,
 
Christoph Aebi, MD
10
, Christoph Berger, MD
4
,
 
Jacques Fellay, MD, PhD
1,2,24
,
 
Luregn J 
Schlapbach, MD
10,25,26,27 
for the EUCLIDS consortium and the Swiss Paediatric Sepsis Study  
*contributed equally  
1. Swiss Institute of Bioinformatics, Lausanne, Switzerland  
2. Global Health Institute, School of Life Sciences, École Polytechnique Fédérale de 
Lausanne (EPFL), Lausanne, Switzerland. 
3. Neonatal Intensive Care Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy 
4. University Children’s Hospital Zurich and the Children’s Research Center, Zurich, 
Switzerland 
5. University of Zurich, Zurich, Switzerland 
6. Division of Genetics and Rheumatology, Brigham and Women's Hospital, Harvard Medical 
School, Boston, Massachusetts, USA. 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa290/5809292 by U
niversitaetsbibliothek Bern user on 25 M
arch 2020
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
14
23
43
 
| 
do
wn
lo
ad
ed
: 
29
.4
.2
02
0
  2 
7. Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, 
Massachusetts, USA. 
8. Imperial College London, Section of Paediatrics, London, United Kingdom. 
9. Imperial College London, Section of Virology, London, United Kingdom. 
10. Department of Paediatrics, Bern University Hospital, Inselspital, University of Bern, 
Bern, Switzerland 
11. Service of Neonatology, Department Woman-Mother-Child, and Infectious Diseases 
Service, Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland  
12. Department of Paediatrics, Children’s Hospital Lucerne, Lucerne, Switzerland 
13. Paediatric Infectious Diseases Unit, Children’s Hospital of Geneva, University Hospitals 
of Geneva, Geneva, Switzerland 
14. Infectious Diseases and Vaccinology, University of Basel Children’s Hospital, Basel, 
Switzerland 
15. Children’s Hospital Aarau, Aarau, Switzerland 
16. Children’s Hospital of Eastern Switzerland St. Gallen, St. Gallen, Switzerland 
17. Department of Neonatology, University Hospital Zurich, Zurich, Switzerland  
18. Department of Paediatrics, Cantonal Hospital Graubuenden, Chur, Switzerland 
19. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland 
20. Translational Paediatrics and Infectious Diseases Section- Paediatrics Department, 
Santiago de Compostela, Spain. 
21. Instituto de Investigación Sanitaria de Santiago (IDIS), Genetics- Vaccines- Infectious 
Diseases and Paediatrics research group GENVIP, Santiago de Compostela, Spain. 
22. Academic Medical Center – Emma Children’s Hospital, University of Amsterdam, 
Amsterdam, The Netherlands 
23. Institute of Molecular Biosciences, The University of Queensland, Brisbane, Australia 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa290/5809292 by U
niversitaetsbibliothek Bern user on 25 M
arch 2020
  3 
24. Precision Medicine Unit, Lausanne University Hospital, Lausanne, Switzerland 
25. Faculty of Medicine, The University of Queensland, Brisbane, Australia 
26. Paediatric Critical Care Research Group, Child Health Research Centre, The University 
of Queensland, Brisbane, Australia 
27. Paediatric Intensive Care Unit, Queensland Children’s Hospital, Children’s Health 
Queensland, Brisbane, Australia 
 
Correspondence A/Prof. Luregn J Schlapbach, MD, FCICM, Paediatric Critical Care Research 
Group, Child Health Research Centre, The University of Queensland, South Brisbane QLD 4101 
Australia; Phone +61 (07) 3068 1111; email: l.schlapbach@uq.edu.au 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa290/5809292 by U
niversitaetsbibliothek Bern user on 25 M
arch 2020
  4 
 
 
Summary In this population-based cohort, whole-exome sequencing identified known and 
unknown rare predicted pathogenic variants in primary immunodeficiency genes in one of five 
children with proven sepsis. Future studies need to validate whether these variants contribute to sepsis 
susceptibility.  
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Abstract  
Background: The role of primary immunodeficiencies (PID) in susceptibility to sepsis remains 
unknown. It is unclear whether children with sepsis benefit from genetic investigations. We 
hypothesized that sepsis may represent the first manifestation of underlying PID. We applied whole-
exome sequencing (WES) to a national cohort of children with sepsis to identify rare, predicted 
pathogenic variants in PID genes. 
Methods: Multicenter population-based prospective study including previously healthy children ≥28 
days and <17 years admitted with blood culture-proven sepsis. Using a stringent variant filtering 
procedure, analysis of WES data was restricted to rare, predicted pathogenic variants in 240 PID 
genes for which increased susceptibility to bacterial infection has been reported.  
Results: 176 children presenting with 185 sepsis episodes underwent WES (median age 52 months, 
IQR 15.4-126.4). 41 unique predicted pathogenic PID variants (1 homozygous, 5 hemizygous, and 35 
heterozygous) were found in 35/176 (20%) patients, including 3/176 (2%) patients carrying variants 
which were previously reported to lead to PID. The variants occurred in PID genes across all 8 PID 
categories as defined by the International Union of Immunological Societies. We did not observe a 
significant correlation between clinical or laboratory characteristics of patients and the presence or 
absence of PID variants. 
Conclusions: Applying WES to a population-based cohort of previously healthy children with 
bacterial sepsis detected Variants of Uncertain Significance in PID genes in one out of five children. 
Future studies need to investigate the functional relevance of these variants to determine whether 
variants in PID genes contribute to pediatric sepsis susceptibility.  
Keywords child; exome sequencing; genomics; immunodeficiency; sepsis; variant; variants of 
uncertain significance 
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Introduction 
The incidence of sepsis is highest at the extremes of age, in the very young and the very old [1-3]. In 
high income countries, 35 to 50% of pediatric sepsis deaths occur in previously healthy infants and 
children despite access to vaccination, health care, and effective antibiotics [2, 4]. Sepsis-related 
morbidity in the absence of risk factors remains high and is associated with significant sequelae such 
as amputations and neurodevelopmental disability [5]. The mechanisms underlying susceptibility to 
severe infectious diseases in otherwise healthy patients remain largely unknown, but epidemiological 
studies suggest a strong genetic contribution [6]. It has been proposed that severe infections in 
childhood are more likely to be the manifestation of rare, single-gene disorders, compared with 
infections occurring in adults [7, 8]. Case reports anecdotally show that life-threatening infections of 
childhood may represent the first manifestation of primary immunodeficiency (PID) [8]. However, 
little is known about the prevalence of PID gene variants in patients with sepsis, and there is a lack of 
guidance to advise on genetic or immunologic investigations after a first sepsis episode [9, 10].  
Whole-exome sequencing (WES) has emerged as a powerful tool to identify disease-causing genetic 
variants [11, 12]. We recently reported successful application of WES in a highly selected cohort of 
pediatric sepsis cases [9]. WES has never been used to assess the genetic contribution to sepsis in 
larger population-based cohorts.  
Although WES is insufficient to determine the functional relevance of genetic variants, it enables their 
identification in PID genes previously reported to be associated with bacterial infection. We 
hypothesized that rare and predicted pathogenic genetic variations in PID genes which are associated 
with bacterial infection are more common in previously healthy children who develop blood culture-
positive community-acquired sepsis compared with genomic reference cohorts.   
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Methods 
Study design 
We conducted a prospective observational multicenter cohort study enrolling children presenting with 
blood culture-proven bacterial sepsis in the ten major pediatric hospitals in Switzerland between 
September 1, 2011, and December 31, 2015. The study protocol and details of the Swiss Pediatric 
Sepsis Study have been reported elsewhere [13, 14]. Written informed consent for genetic analyses 
was obtained from parents or legal guardians. The ethical review board approved the study (Cantonal 
Ethics Committee, University of Bern, KEK-029/11). 
Inclusion criteria: Previously healthy children aged >28 days and <17 years with community-
acquired, blood culture-proven bacterial sepsis due to S. pneumoniae, S. aureus, Group A and B 
streptococcus, N. meningitidis, or H. influenzae, as defined by 2005 pediatric sepsis consensus 
definitions [15] were eligible. These pathogens were selected because they represent the most 
common pathogens causing community-acquired sepsis in children without comorbidities.  
Exclusion criteria: Prematurely born neonates, infants <28 days (or <44 weeks of gestational age) 
and children with comorbidities, including any chronic inborn or acquired medical conditions, known 
primary or secondary immunodeficiency, recent trauma, surgery or burns, and children with hospital-
acquired infection (>48h after admission), or with pathogens other than those listed under inclusion 
criteria were not considered for WES. 
WES, read mapping, variant calling and variant annotation  
Blood samples were collected and processed as reported elsewhere [9]. WES was performed 
on Illumina HiSeq 2500 at the Lausanne Genomic Technology Facility (Supplementary 
Methods and supplementary tables 1, 2 and 3). Sequencing reads were mapped to the 
human reference genome hg19 using BWA-MEM v0.7.15 [16, 17]. The Genome Analysis 
ToolKit v3.8 Sequence Data Processing Tools and Variant Discovery Tools were used 
according its best practices [18, 19]. These included base quality score recalibration and per-
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sample, simultaneous calling of single nucleotide variants and small insertions and deletions 
(indels) with the HaplotypeCaller tool, followed by joint genotyping and quality filtering 
(only variants with genotype quality >100 and read depth >20 were kept for downstream 
analysis). Genetic and functional annotation included putative effect prediction for Sequence 
Ontology terms, putative loss-of-function prediction, and effect predictions from multiple 
algorithms. Each variant was annotated with information on minor allele frequency (MAF) in 
several public databases, including the 1000 genomes project phase 1 (n=1092), the NHLBI 
exome sequencing project (n=7520), the Genome Aggregation Database (gnomAD, 
n=138632), and 519 in-house control exomes.  
Filtering and identification of candidate genomic variants in PID genes  
Analyses were restricted to non-synonymous exonic variants that are rare in the general 
population (MAF <0.01 for homozygous/hemizygous and <0.0001 for heterozygous variants 
in gnomAD database). We also filtered out variants with a MAF >0.01 in our in-house exome 
database. We restricted the analysis to variants in 240 PID genes previously reported to be 
associated with bacterial disease as defined by the International Union of Immunological 
Societies (IUIS) [20]. We further prioritized variants by filtering for predicted pathogenicity, 
keeping only variants with a putative deleterious impact according to Combined Annotation 
Dependent Depletion (CADD) v1.3 score [21], resulting in putatively pathogenic variants. 
For every putatively pathogenic variant, PubMed entries between 1.1.1970 and 30.6.2019 
were searched for reports on patients with PID and bacterial infections carrying the exact 
variant. The study did not include functional validation. Therefore, the filtered rare and 
predicted pathogenic variants in the selected PID genes were labelled “variants of uncertain 
significance” (VUS). 
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Statistical analysis 
Descriptive statistics are presented as median and interquartile ranges (IQR) for continuous variables 
and frequencies and percentages for categorical variables. We used the  2 test of proportions and the 
Wilcoxon non-parametric rank sum test to compare subgroups. We considered a 2-sided p-value of 
<0.05 as significant. Analyses and graphs were done using R (R Core Team (2019). R Foundation for 
Statistical Computing, Vienna, Austria. https://www.R-project.org/). 
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Results 
Cohort description 
During the study period, out of 1,275 blood culture-proven sepsis episodes, 383 occurred in 380 
previously healthy children (Figure 1). S. pneumoniae, S. aureus, Group A and B streptococcus, N. 
meningitidis, and H. influenzae accounted for 271/383 (70%) of sepsis episodes. 94 patients were 
excluded, predominantly because of lack of consent or lack of access to DNA. One case of H. 
influenzae B sepsis in an unvaccinated child was excluded. The final WES cohort consisted of 176 
children including 8 (5%) with recurrent bacterial sepsis (Table 1). 38% of patients developed organ 
dysfunction and 37% required PICU admission for sepsis. 5/176 (2.8%) children died. 
Identification of putatively causative PID variants 
WES was successfully performed in all 176 study participants. In total, 8,463,144 variants were 
identified. After filtering based on predicted function impact, predicted pathogenicity and MAF, 
35,966 variants were retained (supplementary figure 1). We then restricted analyses to rare variants 
in 240 PID genes known to be associated with bacterial infection: 41 unique rare and predicted 
pathogenic VUS were identified in 35 out of 176 participants (20%) across 24 PID genes (Table 2 
and supplementary figure 2). Biallelic (homozygous) variants were found in 1 participant in 1 gene, 
X-linked variants in 5 participants in 5 genes, and monoallelic variants were found in 35 study 
participants in 18 genes. In 30/35 patients (86%), only one variant was found whereas in 5/35 (14%) 
patients two or three variants were discovered. Out of the 41 variants, 3 exact variants in 3/176 
participants (2%) were identical to previously reported variants from patients with a PID phenotype 
with bacterial infection (Table 3).  
Characterization and distribution of PID gene variants in children with sepsis 
The identified variants were distributed across all PID groups (Table 2, supplementary figures 2 
and 3 and supplementary table 4)[20]. They were most commonly found in CHD7 (n=6 patients), 
and SAMD9, TCF3 and BACH3 (n=3 each). The 3 previously reported PID variants related to 
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combined immunodeficiencies with associated symptoms, phagocyte defects, and complement defects 
(Table 3). 
We did not observe any association of variants with specific pathogens or focus of infection (Table 1, 
p>0.10). They were found in 13 out of 54 patients with S. pneumoniae infection (24%), in 7 out of 44 
patients with S. aureus infection (16%), in 6 out of 33 patients with Group A streptococcal infection 
(18%), in 4 out of 17 patients with Group B streptococcal infection (24%), in 2 out of 16 patients with 
N. meningitidis infection (13%), and in 3 out of 12 patients with H. influenzae infection (25%) (Table 
2, supplementary figures 2 and 3). There was no significant difference in the proportion of children 
found to carry PID variants between children <2 years (12/56, 21%) and children >2 years of age 
(23/120, 19%, p = 0.8). Figure 2 and supplementary figure 4). No significant differences were 
observed when comparing the proportion of children with and without different PID variants in 
relation to presence of organ dysfunction, PICU admission, frequency of leukopenia or the maximum 
C-reactive protein level measured during sepsis (Table 1). Variants were found in 4/8 (50%) patients 
with recurrent sepsis versus 31/168 (18%) in children without recurrent sepsis (p = 0.051 Fisher test).   
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Discussion 
In this prospective, population-based cohort of previously healthy children presenting with blood 
culture-proven bacterial sepsis, rare variants in genes previously reported to lead to PID associated 
with bacterial infection were substantially more common than previously assumed. It is important to 
note that the variants identified in our study are predicted but not functionally confirmed to affect 
gene function and lead to immunodeficiency. Therefore, they must be considered variants of uncertain 
significance (VUS). Importantly, around one out of fifty (3/176; 2%) of children with community-
acquired sepsis that underwent WES carried exact variants that have been previously shown to result 
in PID associated with bacterial infections, which is higher than the estimated prevalence of PID in 
the population [22]. The variants identified in PID genes were distributed across all main IUIS 
categories [20]. We did not observe specific patterns in terms of pathogens, severity, inflammatory 
markers, or age at presentation that associated with the likelihood to detect such variants. These VUS 
in genes previously linked to susceptibility to bacterial infections within the context of clearly defined 
PID were found in otherwise apparently healthy children with bacterial sepsis. This finding may be 
explained either by lack of functional relevance or by pleiotropy.  WES represents a promising first-
step to investigate children with sepsis for potentially underlying PID. Future studies should combine 
WES with in-depth functional assays. 
 
Understanding why a minority of children become very ill in the course of an infection remains one of 
the mysteries of sepsis and may harbor clues for future targeted interventions [23].  Casanova et al 
previously stated the hypothesis that life-threatening infections of childhood may represent the first 
manifestation of PID [8]. Identification of PID in children with sepsis due to community-acquired 
bacteria has been reported in highly selected cases caused by Pseudomonas aeruginosa [9, 24, 25] or 
S. pneumoniae. A French study investigated 163 children with pneumococcal disease using 
conventional immunologic screening reported underlying PID in 10% of cases [26], with a higher 
proportion of PID found in children >2 years of age. Monogenic diseases resulting in PID have shown 
to be associated with selected invasive bacterial infections, including Group B streptococcal and 
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staphylococcal infections [27]. Several non-conventional PID, such as IRAK-4, MyD88 and TIRAP 
deficiency [28-30], are characterized by incomplete penetrance and variable pathogen specificity. The 
effect of some PID on increased susceptibility to infection may decrease with age if patients survive 
infections during childhood [28]. In our study, we did not find any association between presence of 
PID VUS and increased disease severity, measured by need for PICU admission, number of organ 
dysfunctions, or septic shock [31]. Blood culture-proven sepsis represents an extreme phenotype from 
an evolutionary perspective given the high fatality rate of bacteremia in the absence of antimicrobial 
therapy. In contrast, extreme phenotypes as defined by contemporary medicine with the availability of 
intensive care support are subject to different host genetic, pathogen, and environmental factors. 
Importantly, time to antibiotics represents a major determinant of severity [4, 32], and the specific 
setting in Switzerland has to be considered, including a low proportion of socioeconomically 
disadvantaged children, and a high-density pediatric hospital network, potentially resulting in earlier 
treatment.  
Children requiring life support due to severe infections in PICUs are currently not routinely 
investigated for the presence of PIDs. No specific guidelines exist for clinicians when facing the 
question if a child with sepsis may harbor a PID [10]. There is a need for studies defining indications 
for PID investigations in children with sepsis; coupled with increased education and awareness of 
pediatric intensivists, infectious disease specialists, and pediatricians on the topic. Selection rules 
based on pathogens, severity, or a history of familial reoccurrence alone could be inaccurate, as 
demonstrated by the absence of clear patterns in our study. In addition, commonly used 
immunological investigations, such as the measurement of total and specific immunoglobulin, 
complement protein concentrations and basic lymphocyte populations will miss a substantial 
proportion of PID in comparison to WES. Importantly, recognizing and accurately diagnosing 
underlying PID in children presenting with sepsis is important given the risk of recurrence of 
infection, with potentially fatal but preventable outcome [9]. The challenges in interpreting the 
findings of our study highlight that while next generation sequencing (NGS) represents a promising 
diagnostic tool in children with sepsis, NGS-based genetic testing must be followed by specifically 
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indicated functional tests if WES is to be considered as a routine diagnostic approach. Validation of 
the findings will require immunological follow-up of the study cohort, including assessment of 
subsequent invasive infections. Unfortunately, the study approval was restricted to singleton testing. 
Future studies embarking on unravelling the genetic contribution to childhood sepsis need to 
incorporate functional analyses both during disease and (if the patient survives) during recovery, 
including extended investigations of parents and siblings as indicated. In view of our findings of a 
high number of VUS across all IUIS categories, the availability of immune-phenotyping platforms to 
assess a broad range of immunological pathways carries strong promise [33].   
NGS has been successfully applied both to discover novel disease-causing gene variants and to obtain 
a molecular diagnosis of monogenic conditions [34, 35], and may be cost effective in comparison to 
standard genetic diagnostic procedures [35]. Yet, as a result of the increasing number of patients 
undergoing WES [11, 36], the field of clinical immunology is rapidly evolving, and expanding 
cohorts demonstrate considerable variability of the phenotypes. The mechanisms underlying 
incomplete penetrance and variable expressivity remain mostly unexplained and are likely complex, 
as demonstrated by the recent discovery of the role of anti-LTA antibody deficiency in patients with 
TIRAP deficiency [27]. We applied stringent filtering criteria including several control cohorts, and 
restricted analyses to rare variants predicted to have functional impact in genes known to lead to PID 
phenotypes associated with bacterial infection. Despite this approach, confirming that rare VUS 
identified by WES are pathogenic remains a challenge [12, 37]. Rare variants in genes previously 
demonstrated to result in Mendelian disease may also contribute to the risk of infection through 
complex and polygenic mechanisms [38]. A recent landmark study using electronic health record 
based phenotype risk scores in large genotyped cohorts identified a substantial number of 
undiagnosed patients harboring rare variants and phenotypes related to unrecognized Mendelian 
diseases [39]. Combination of international cohorts will be required to provide the power for 
statistical validation of enriched variants or pathways, or to test the hypothesis that complex/polygenic 
predisposition could also play a role in human susceptibility to sepsis.  
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Despite these challenges, our findings are based on a high-quality prospective population-based study 
restricted to the gold-standard of invasive infection (bacteraemia). The design of this national cohort 
minimized inclusion bias in comparison to the majority of immunologic studies, commonly based on 
highly selected referral patients with severe or recurrent disease. We carefully excluded children with 
underlying comorbidities, in order to focus on community-acquired sepsis in children that were 
apparently healthy before hospital admission. We acknowledge that this may have led to the exclusion 
of children harboring PID associated with congenital disease or syndromes. We restricted WES to the 
most common pathogens causing community-acquired sepsis [14], and acknowledge that PIDs 
potentially may be more common in children presenting with unusual bacterial pathogens. 
Our study has several additional limitations. Most importantly, we did not functionally verify the 
pathogenicity of the variants identified in PID genes. While we used stringent filtering and 
pathogenicity prediction criteria aligned with best practice, and assessed whether variants had been 
previously demonstrated to lead to PID with bacterial infection, their pathogenicity has not been 
demonstrated, thus resulting in a possible overestimation of the proportion of PID-related sepsis. 
Functional validation in our and other independent cohorts will be required to define the true 
proportion of PID causing sepsis in children. Second, we only focused on PID genes previously 
demonstrated to be associated with bacterial infection, which may have led to exclusion of causative 
variants, thereby resulting in an underestimation of the proportion of PID-related sepsis. In addition, 
the genetic background for several PID, mainly disorders affecting antibody production, is unknown, 
which may again result in an underestimation of PID. Considering the rapid expansion of recently 
identified novel PID, it is thus also likely that a subset of patients may harbor disease-conferring yet 
unidentified novel PID. Experimental validation to define the causal relationship between genotype 
and phenotype is crucial during the investigation of novel PID candidates. Third, an intrinsic 
limitation in WES is the inability to detect deep intronic and intergenic genetic variants. Finally, we 
did not assess microbiological factors determining pathogen virulence, such as toxins. 
In conclusion, applying WES to a population-based cohort of previously healthy children presenting 
with bacterial sepsis allowed the detection of VUS in previously reported PID genes in a substantial 
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proportion of sepsis cases. Our study explores the possible contribution of host genetic variation to 
sepsis susceptibility. Future studies combining NGS with functional testing are required to validate 
whether unrecognized PIDs contribute significantly to sepsis at the populational level. Our findings 
indicate an urgent need for evidence-based recommendations on the optimal selection of children with 
sepsis for genetic and functional investigations to identify PIDs.   
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Figure legends 
Figure 1. Enrolment flow diagram of whole-exome sequencing (WES) cohort. Patients 
undergoing WES were previously healthy children with blood-culture proven sepsis caused by S. 
pneumoniae, S. aureus, Group A streptococcus, Group B streptococcus, N. meningitidis and H. 
influenzae. CVC, central venous line; GBS, Group B streptococcus; PCR, polymerase chain reaction; 
SPSS, Swiss Pediatric Sepsis Study. 
 
Figure 2. Number of previously healthy children with blood-culture proven sepsis in relation to 
age and severity at presentation. Children testing positive for a rare Variant of Uncertain 
Significance (VUS) associated with primary immunodeficiency are shown in blue, in 
comparison to children where no VUS associated with primary immunodeficiency was found, 
shown in grey. HI, Haemophilus influenzae; NM, Neisseria meningitidis; GBS, Group B 
streptococcus; GAS, group A streptococcus; SA, Staphylococcus aureus; SP, Streptococcus 
pneumoniae. 
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Table 1 - Demographic and clinical characteristics of children with blood culture-
proven bacterial sepsis in relation to whole exome sequencing findings of putatively 
pathogenic variants in known primary immunodeficiency (PID) genes. Characteristics of 
children without a primary immunodeficiency (PID) variant (n=141) are compared to 
children in whom a PID Variant of Uncertain Significance was found (n=35, including novel 
and previously reported PID variants), and children in whom a previously reported PID 
variant was found (n=3). 
 
 
All children 
(n=176, 100%) 
Children 
without PID 
variants 
(n=141, 80%) 
Children with 
PID Variants of 
Uncertain 
Significance 
(n=35, 20%) 
Children with 
previously 
reported PID 
variant 
(n=3, 2%) 
Demographics     
Age at sepsis 
onset (months) 
51.9 (15.3 - 
126.5) 
54.5 (15.4 - 
127.2) 
40.2 (9.1 - 111.7) 
128.3 (27.5 - 
170.4) 
Age group     
28-365 days 41 (23%) 32(23%) 9(26%) 1(33%) 
1-4 years 53 (30%) 42(30%) 11(31%)  
5-9 years 35 (20%) 28(20%) 7(20%)  
10-16 years 47 (27%) 39(28%) 8(23%) 2(67%) 
Male 112 (64%) 87(62%) 25(71%) 2(67%) 
Ethnicity
a
     
Caucasian 159 (90%) 127(90%) 32(91%) 3(100%) 
Asian 4 (2%) 3(2%) 1(3%)  
African 4 (2%) 4(3%)   
other 3 (2%) 3(2%)   
Site of infection     
Primary 
bloodstream 
infection 
22 (12%) 19(13%) 3(9%)  
Pneumonia 47 (27%) 39(28%) 8(23%) 1(33%) 
Bone and joint 
infection 
37 (21%) 30(21%) 7(20%) 1(33%) 
Central nervous 
system infection 
33 (19%) 23(16%) 10(29%) 1(33%) 
Skin and soft 
tissue infection 
15 (9%) 12(9%) 3(9%)  
Ear, Nose, and 
Throat infection 
9 (5%) 6(4%) 3(9%)  
Toxic shock 
Syndrome 
4 (2%) 4(3%)   
Gastrointestinal 
system infection 
2 (1%) 2(1%)   
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All children 
(n=176, 100%) 
Children 
without PID 
variants 
(n=141, 80%) 
Children with 
PID Variants of 
Uncertain 
Significance 
(n=35, 20%) 
Children with 
previously 
reported PID 
variant 
(n=3, 2%) 
Urinary tract 
infection 
1 (1%) 1(1%)   
Other specific 
infection type 
6 (3%) 5(4%) 1(3%)  
Pathogens     
Gram positive 
bacteria 
148 (84%) 118(84%) 30(86%) 3(100%) 
S. 
pneumoniae 
54 (31%) 41(29%) 13(37%) 2(67%) 
S. aureus 44 (25%) 37(26%) 7(20%) 1(33%) 
Group A 
streptococci 
33 (19%) 27(19%) 6(17%)  
Group B 
streptococci 
17 (10%) 13(9%) 4(11%)  
Gram negative 
bacteria 
28 (16%) 23(16%) 5(14%)  
N. 
meningitidis 
16 (9%) 14(10%) 2(6%)  
H. influenzae 12 (7%) 9(6%) 3(9%)  
Severity of sepsis     
Organ 
dysfunction 
    
No organ 
dysfunction 
present 
108 (61%) 89(63%) 19(54%) 1(33%) 
≥ 1 organ 
dysfunction 
68 (39%) 52(37%) 16(46%) 2(67%) 
C-reactive 
protein (mg/L)
b
 
192 (94 - 260) 186 (95 - 266) 198 (88 - 237) 192 (165 - 200) 
Leukopenia 
present
c
 
30 (17%) 21(15%) 9(26%) 1(33%) 
PICU/ NICU 
admission 
66 (38%) 53(38%) 13(37%) 2(67%) 
Length of PICU 
stay (days) 
5 (2 - 9) 4 (2 - 9) 7 (2 - 12) 19 (2 - 36) 
Length of 
hospital stay 
after sepsis 
onset (days) 
10 (7 - 15) 10 (7 - 15) 11 (7 - 15) 10 (6 - 55) 
Invasive 
ventilation 
36 (20%) 29(21%) 7(20%) 1(33%) 
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All children 
(n=176, 100%) 
Children 
without PID 
variants 
(n=141, 80%) 
Children with 
PID Variants of 
Uncertain 
Significance 
(n=35, 20%) 
Children with 
previously 
reported PID 
variant 
(n=3, 2%) 
Inotrope 
requirement 
39 (22%) 31(22%) 8(23%) 2(67%) 
Case fatality 6 (3%) 5(4%) 1(3%)  
a
Data not available in 6 episodes, 
b
Data not available in 9 episodes, 
c
Data not available in 3 episodes. 
PICU=pediatric intensive care unit. NICU=neonatal intensive care unit. 
Categorical variables are given as frequencies and percentages, continuous variables as median and 
interquartile range. Column percentages are given. Percentages are based upon available data for each 
variable. 
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Table 2.  Clinical characteristics of children with blood culture-proven bacterial sepsis 
where a Variant of Unknown Significance in a primary immunodeficiency (PID) gene 
was found (n=35) are shown for each PID according to the IUIS classification. 
 
Gene Inheriten
ce 
Uniqu
e 
varian
ts 
Uniqu
e 
patien
ts 
Age in mo 
[mean, 
range] 
Sex Clinical focus Organ 
dysfuncti
on 
Primary pathogen 
cultured 
            
X
L 
A
R 
A
D 
M F CN
S 
EN
T 
Pneumo
nia 
Bon
e/ 
joint 
Cellulit
is 
Othe
r 
No  
focu
s 
0 ≥1 H
I 
N
M 
GB
S 
GA
S 
S
A 
S
P 
CID/CID
+ 
                       
BCL11B   2 2 2 84 (75,93) 2    1 1      1 1    1  1 
CHD7   6 6 6 61 (2,148) 5 1 3  1 2     2 4  1 1 1 2 1 
KDM6A 1    1 1 31 (31,31) 1     1      1        1 
KMT2D   2 2 2 100 
(34,167) 
 2   1  1    1 1    1 1  
SAMD9   3 3 3 16 (1,40) 2 1 2     1   1 2  1 1 1   
SEMA3E   1 1 1 14 (14,14) 1   1         1 1      
STAT3   1 1 1 34 (34,34)  1   1      1        1 
TBX1   1 1 1 6 (6,6) 1   1        1        1 
WAS 1    1 1 7 (7,7) 1   1         1      1 
PAD/PIR
D 
                            
IRF2BP2   1 1 1 148 
(148,148) 
1      1     1       1  
NFKB2   2 2 2 88 (43,132) 2      2     2       1 1 
PTEN   1 1 1 132 
(132,132) 
 1 1         1      1 
TCF3   3 3 3 63 (2,100) 3    1   1  1 3     1 1  1 
TNFRSF1
3B 
  1 1 1 64 (64,64) 1     1      1        1 
BACH2   3 3 3 109 
(23,176) 
3     1 2     2 1 1    2  
NFAT5   1 1 1 5 (5,5)  1 1         1      1 
PD/IID                             
CYBB 1    1 1 128 
(128,128) 
1      1     1       1  
CXCR4   2 2 2 41 (34,48)  2   1 1      2    2   
IL17F   1 1 1 112 
(112,112) 
 1     1    1      1   
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IRAK1 1    1 1 4 (4,4) 1         1 1       1  
AID/CD                             
PLCG2   2 2 2 109 
(75,143) 
1 1   2      1 1      2 
POLA1 1    1 1 109 
(109,109) 
1      1     1       1  
C4A  1   1 1 5 (5,5) 1         1 1     1    
CFH     2 2 2 108 
(38,179) 
1 1   1 1           2 1         1 
XL, X-linked; AR, autosomal-recessive; AD, autosomal-dominant; M, male; F, female; CNS, central nervous system (infection); ENT, ear 
nose throat (infection); LRTI, lower respiratory tract infection; HI, Haemophilus influenzae; NM, Neisseria meningitidis; GBS, Group B 
streptococcus; GAS, Group A streptococcus; SA, Staphylococcus aureus; SP, Streptococcus pneumoniae. 
CID, combined immunodeficiencies; CID+, CID with associated symptoms; PAD, predominantly antibody disorders; PIRD, primary 
immune dysregulatory disorders; PD, phagocyte defects; IID, innate immune defects; AID, autoinflammatory disorders; CD, complement 
defects. 
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Table 3. Rare variants previously reported in patients with primary immunodeficiency (PID) 
and bacterial infections which were found in children with blood culture-proven sepsis. Host and 
pathogen characteristics of the sepsis episodes (n=3) where a patient was found to carry a previously 
reported PID variant associated with bacterial infection, and details of the identified variants are 
shown. 
 
IUIS 
catego
ry 
Sex Age 
(days
) 
Pathog
en 
Clinica
l focus 
Gene HGVS.p Inhe
ri-
tanc
e 
Read 
dept
h 
Frequenc
ies  
in 
gnomAD 
Pubmed ID 
CID+ M 223 SP CNS WAS E131K 
(p.Glu131Lys
) 
XL 25 0,002600
66 
missense variant 
(15284122) 
PD M 3905 SA bone/jo
int 
CYB
B 
G364R 
(p.Gly364Arg
) 
XL 40 0.003946
64 
missense variant 
(10089913) 
CD F 5443 SP pneum
onia 
CFH P503A 
(p.Pro503Ala) 
AD 176 1,63E-05 missense variant 
(24906858) 
F, female; M, male; HI, Haemophilus influenzae; NM, Neisseria meningitidis; GBS, Group B streptococcus; 
GAS, group A streptococcus; SA, Staphylococcus aureus; SP, Streptococcus pneumoniae; AD, autosomal-
dominant; AR, autosomal-recessive; XL, X-linked  
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Figure 1 
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Figure 2 
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